Novo Nordisk Inc. disclosed a total of $1.29 million in federal lobbying expenditures for the first quarter of 2026, according to a formal filing submitted on April 21, 2026, under the Lobbying Disclosure Act. The expenditure represents the company's primary investment in legislative and regulatory advocacy during the three-month period ending March 31, 2026. The filing provides a detailed account of the company's interactions with the legislative and executive branches regarding healthcare policy and pharmaceutical regulation.
The disclosure highlights a concentrated effort by the Danish pharmaceutical firm to influence federal policy regarding the coverage and reimbursement of metabolic health treatments. A significant portion of the advocacy was directed toward the Treat and Reduce Obesity Act (TROA). This legislation aims to amend the Social Security Act to expand Medicare Part D coverage to include FDA-approved medications for chronic weight management, a category that includes Novo Nordisk’s semaglutide-based product, Wegovy. Currently, Medicare is prohibited by law from covering drugs specifically for weight loss, making the advancement of TROA a central pillar of the company’s long-term policy strategy.
Beyond obesity care, the Q1 2026 filing details Novo Nordisk’s engagement with the implementation of the Inflation Reduction Act (IRA). The company’s lobbyists met with officials from the Department of Health and Human Services (HHS) and the Centers for Medicare & Medicaid Services (CMS) to discuss the Medicare Drug Price Negotiation Program. The discussions focused on the selection criteria for drugs subject to price caps and the transparency of the maximum fair price determination process. Novo Nordisk has consistently advocated for policies that protect intellectual property rights and maintain incentives for pharmaceutical innovation amid these federal price controls.
The report also lists activity related to the 340B Drug Pricing Program and Pharmacy Benefit Manager (PBM) reform. Novo Nordisk has been active in seeking legislative clarity on the use of contract pharmacies, following several years of regulatory shifts and legal challenges. Regarding PBMs, the company’s advocacy focused on proposals to reform the rebate system. The company reported lobbying on specific bills that would require PBMs to pass through a greater percentage of manufacturer rebates to patients at the point of sale, a move the company suggests would lower out-of-pocket costs for insulin and other essential medications.
The $1.29 million total includes the costs of maintaining an in-house government affairs team as well as the retention of several prominent Washington D.C.-based lobbying firms. These external consultants provided expertise on healthcare appropriations and monitored activity within the Senate Committee on Health, Education, Labor, and Pensions (HELP) and the House Energy and Commerce Committee. The filing was signed by the company’s designated disclosure officer and complies with all federal reporting requirements for the period, serving as a mandatory periodic disclosure of the company's political and policy-related activities.